In an announcement made this morning, the Melbourne-based company revealed its OmniCAR platform continues to demonstrate several key attributes in early studies. These attributes include…

Prescient Therapeutics Limited (ASX:PTX) is presenting new preclinical data on OmniCAR at the Cell & Gene Meeting on the Mesa in Carlsbad, California. Bringing together…

Prescient Therapeutics (PTX) will present new results for its OmniCAR drug at the Cell & Gene Meeting on Mesa in California. The conference brings together…

ASX-listed oncology player, Prescient Therapeutics Limited (ASX:PTX) is developing personalised medicines for difficult to treat cancers having unmet medical needs. The innovative product pipeline of…

Dr Rebecca Lim, Director of Scientific Affairs at Prescient Therapeutics (ASX: PTX), presented at the fifth annual Cell & Gene Therapy World Asia Conference 2021 last…

This year, the ASX healthcare index gained a little more than 10% year to date. The healthcare index acts as a benchmark for investors, reflecting…

Australian biotech company Prescient Therapeutics has achieved numerous milestones in the past financial year as it advances the development of its cancer-fighting treatments. The company…

Australia-based clinical-stage oncology firm Prescient Therapeutics Limited (ASX:PTX) has completed another action-packed year with a sound financial position. The Company ended the year with a…

Steven Yatomi-Clarke from Prescient Therapeutics (ASX:PTX)

Prescient Therapeutics has announced that a global expert in brain cancer, Professor Donald M. O’Rourke, will be joining the company’s Scientific Advisory Board. Professor O’Rourke…